Flow cytometry detection method for circulating tumor cells by using homologous targeting enhanced biological membrane vesicles

Through homologous targeting enhanced biofilm vesicle technology, metal complex modification and HAL excitation of fluorescent signals are used to solve the problems of high cost and low resolution for circulating tumor cells, and efficient and accurate detection of circulating tumor cells is achieved. Suitable for the detection of circulating tumor cells in the blood.

CN118961550APending Publication Date: 2024-11-15CHINA PHARM UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411011621.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing circulating tumor cell detection methods are expensive and difficult to achieve high resolution. Traditional flow cytometry relies on antibody detection, which limits its widespread application. The content of circulating tumor cells in the blood is extremely small, making detection challenging.

Method used

Protoporphyrin IX (PpIX) in tumor cells was stimulated by the metal complex TDA-Co-Ln using hexylamine levulinate hydrochloride (HAL) using homologous targeting enhanced biofilm vesicles. Fluorescence signals, combined with ultrasonic rupture and flow cytometry detection, achieve efficient and accurate detection of circulating tumor cells.

Benefits of technology

It realizes low-cost and accurate circulating tumor cell detection, improves the sensitivity and specificity of detection, can detect single-cells, shortens detection time and reduces detection costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004964536350000011
    Figure HDA0004964536350000011
  • Figure HDA0004964536350000012
    Figure HDA0004964536350000012
  • Figure HDA0004964536350000013
    Figure HDA0004964536350000013
Patent Text Reader

Abstract

The invention discloses a method for detecting circulating tumor cells by using homologous targeting enhanced biological membrane vesicles, which comprises the following steps: taking tumor cells to prepare biological membrane vesicles, and modifying the biological membrane vesicles by using 5-aminolevulinic acid hexyl ester hydrochloride and a metal complex TDA-Co-Ln to obtain targeting enhanced biological membrane vesicles, the targeting enhanced biological membrane vesicle has enhanced homologous targeting ability, and can efficiently deliver HAL into circulating tumor cells in blood in a targeting manner; then, the captured target circulating tumor cells are released through ultrasonication, HAL is released into 106 tumor cells, then PpIX accumulation is generated in the tumor cells through a heme biosynthesis route, 103-104 tumor cells emit red fluorescence signals, the fluorescence signals of the tumor cells are detected through a flow cytometry, and the fluorescence signals of the tumor cells are obtained. And calculating to obtain the number of the target CTCs in the blood.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a method for detecting circulating tumor cells using biomembrane vesicles enhanced by homologous targeting. Background Art

[0002] Circulating tumor cells (CTCs) are a type of tumor cells that shed from primary tumors or metastatic tumors and circulate in the peripheral blood. In the early stages of tumorigenesis, circulating tumor cells shed by tumors have been found in the patient's blood, so CTCs can be used as an important disease marker for early detection of cancer. During cancer treatment, increased levels of CTCs are also an indicator of cancer progression and can be used to reveal the mechanism of cancer metastasis. In addition, CTCs have been shown to play an important role in the prognosis of many cancers, including breast cancer, prostate cancer, colon cancer, melanoma, and lung cancer. Therefore, the detection of CTCs is of great significance for the early detection, diagnosis, treatment detection, disease assessment, and research on the mechanism of tumor metastasis.

[0003] Circulating tumor cells are present in very small amounts in the body and are usually 4 WBCs and 10 9 There are only 10 circulating tumor cells in 5 mL of blood from a metastatic cancer patient with 10 red blood cells. In addition, due to tumor heterogeneity and potential changes in molecular characteristics during epithelial-mesenchymal transition, circulating tumor cells are heterogeneous, making the detection and analysis of circulating tumor cells extremely challenging. In recent years, a series of new methods for detecting circulating tumor cells have been developed, such as the Cell Search system, immunochemistry, reverse transcription-PCR, and flow cytometry. Flow cytometry can perform multi-parameter, rapid quantitative analysis and sorting of circulating tumor cells, effectively solving the shortcomings of immunochemistry, which is not sensitive to cells, and RT-PCR, which cannot quantify cells. It also solves the shortcomings of the Cell Search system, which relies on single antibody capture and is prone to missing small-sized cells. It is an ideal method for detecting circulating tumor cells.

[0004] Although traditional flow cytometry is a powerful tool for analyzing cell populations, it does not provide the resolution required to detect circulating tumor cells at very low levels. Traditional flow cytometric analysis of circulating tumor cells relies on antibodies binding to specific antigens for their detection, resulting in high costs and complex technical settings required during analysis, which in turn limits their widespread application.

[0005] In summary, the present invention designs and utilizes homologous targeting-enhanced biomembrane vesicles for detecting circulating tumor cells. Summary of the invention

[0006] The object of the present invention is to provide a method for detecting circulating tumor cells, comprising the following steps: Step 1, taking tumor cells and preparing biomembrane vesicles; Step 2, take 10-20 μL of 0.03-0.30 mg / mL biomembrane vesicle solution, add 20-80 μL of 0.05-1.0 mM 5-aminolevulinic acid hexyl ester hydrochloride solution, mix well, then add 8-16 μL of 0.1 mg / mL metal complex TDA-Co-Ln solution, incubate at room temperature for 1-2 h, centrifuge, remove the supernatant, and resuspend the precipitate with 100-200 μL PBS to obtain targeted enhanced biomembrane vesicles; Step 3: Take 50-100 μL of the targeted enhanced biofilm vesicle solution, add 50-100 μL of homologous tumor cell suspension (1-20 cells) / peripheral blood mononuclear cell suspension and 8-16 μL of 0.1 mg / mL metal complex TDA-Co-Ln solution, incubate at 37 °C for 10-90 min, centrifuge, remove the supernatant, ultrasonically disrupt the precipitate (target CTC) to release the HAL, and then mix with 10 6 Tumor cells were incubated for 0.5-6 h, and the fluorescence signals of tumor cells producing PpIX fluorescence were detected by flow cytometry, and the signals were substituted into the established standard curve to calculate the number of circulating tumor cells. The metal complex TDA-Co-Ln is composed of 2,2'-thiodiacetic acid, cobalt ion Co 2+ and lanthanide ions, wherein the lanthanide ions are Eu 3+ or Tb 3+ .

[0007] Furthermore, the biomembrane vesicles are cell membrane vesicles, extracellular vesicles or exosomes.

[0008] Furthermore, the concentration of the 5-aminolevulinic acid hexyl ester hydrochloride solution in step 2 is 0.5 mM.

[0009] Furthermore, in step 3, the targeted enhanced biofilm vesicle solution, the homologous tumor cell suspension, and the metal complex TDA-Co-Ln solution were incubated at 37° C. for 30 min.

[0010] In one embodiment of the present invention, taking MDA-MB-436 cells as an example, it is verified that the targeting of biomembrane vesicles modified with the metal complex TDA-Co-Ln is enhanced, and the addition of the metal complex TDA-Co-Ln during the co-incubation with cells can further enhance the targeting of the biomembrane vesicles. The MDA-MB-436 cell biomembrane vesicles labeled with 5-aminolevulinic acid hexyl ester hydrochloride and the metal complex TDA-Co-Ln can be used to detect circulating tumor cells in MDA-MB-436 cells.

[0011] 5-Aminolevulinic acid hexyl ester hydrochloride (HAL) has been used as a photosensitizer to stimulate the production of protoporphyrin IX (PpIX) in tumors and emit detectable red fluorescence; biological membrane vesicles carry proteins and have intrinsic homing properties to source cells, which can achieve specific targeting; the metal complex TDA-Co-Ln developed by the inventors in the early stage can target sialic acid on the surface of tumor cell membranes to convert Ln 3+ Deposited on the surface of tumor cells, it is used to modify biomembrane vesicles and improve targeting ability. Therefore, biomembrane vesicles modified with HAL and TDA-Co-Ln have enhanced homologous targeting ability and can efficiently deliver HAL to circulating tumor cells in the blood; then, the captured target circulating tumor cells are released by ultrasonic fragmentation, releasing HAL to 10 6 In tumor cells, PpIX accumulates through the heme biosynthesis pathway in tumor cells, causing 10 3 -10 4 Each tumor cell emits a red fluorescent signal, which is then detected by flow cytometry to calculate the number of target CTCs in the blood.

[0012] Different from traditional circulating tumor cell detection methods, such as Figure 1 As shown, the present invention uses biomembrane vesicles of tumor cells (i.e., vesicles, extracellular vesicles, and exosomes prepared by cell membrane extraction) for targeting. Biomembrane vesicles can return to the parent cells that produce them through homologous targeting, and the binding effect of the metal complex TDA-Co-Ln with sialic acid highly expressed on the surface of tumor cells is used to enhance the homologous targeting effect. The complex of biomembrane vesicles and cells is collected by centrifugation to achieve tumor cell enrichment, and the target cells are broken to release HAL and 10 6 Cells were co-cultured to make 10 3 -10 4 Each cell has red fluorescence, which can achieve signal amplification and subsequent flow cytometry analysis.

[0013] Compared with the prior art, the present invention has the following significant features: The present invention provides an efficient, accurate and economical means for detecting circulating tumor cells, which is helpful for the specific detection of circulating tumor cells.

[0014] The present invention utilizes biomembrane vesicles to target tumor cells, does not require aptamers and antibodies, and has low detection costs.

[0015] The present invention adopts lanthanide ions to modify biomembrane vesicles, thereby enhancing the homologous targeting ability of the biomembrane vesicles, improving specificity and shortening detection time.

[0016] The present invention establishes a fluorescence detection method for circulating tumor cells through modification condition optimization, targeting and recovery rate experiments, which can be used for the detection of circulating tumor cells in the blood, has strong targeting, good detection sensitivity, and can achieve single cell detection. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 Schematic diagram of the principle of the detection method of the present invention.

[0018] Figure 2 TEM images of exosomes and cell membranes obtained in Example 1.

[0019] Figure 3 This is the particle size result diagram of EXO-MDA and CM-MDA after TCT modification in Example 1.

[0020] Figure 4 This is a graph showing the results of TCT enhancing homologous targeting in Example 1.

[0021] Figure 5 This is a graph showing the results of incubation time screening in Example 2.

[0022] Figure 6 This is a diagram of the HAL concentration screening results in Example 2.

[0023] Figure 7 This is a diagram showing the biomembrane vesicle targeting results in Example 3.

[0024] Figure 8 This is the sensitivity test curve of the method in Example 3.

[0025] Fig. 9 These are the fluorescence signal values ​​of normal mice and cancer-bearing mice in flow cytometry in Example 4. DETAILED DESCRIPTION

[0026] The preferred embodiments of the present invention will be described in detail below in conjunction with examples. It should be understood that the following examples are provided only for the purpose of illustration and are not intended to limit the scope of the present invention. Those skilled in the art may make various modifications and substitutions to the present invention without departing from the purpose and spirit of the present invention.

[0027] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0028] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources. Example 1

[0029] 1. Extraction of exosomes and cell membranes from MDA-MB-436 cells a: Extraction of exosomes: (1) Collect the culture medium of MDA-MB-436 cells, centrifuge at 3000 g, 4 °C for 15 min, and take the supernatant; centrifuge at 10000 g, 4 °C for 30 min, and take the supernatant; filter with 0.22 μM filter membrane; (2) Add centrifugal supernatant and one-quarter volume of PEG-8000, mix well, and incubate at 4 °C overnight; centrifuge at 6500 g, 4 °C for 20 min, discard the supernatant, and the precipitate is exosomes (EXO-MDA), which is resuspended in 100-200 μL PBS buffer. Figure 2 As shown in center A, exosomes have a disc-shaped morphology.

[0030] b: Extraction of cell membrane: (1) Discard the original culture medium of MDA-MB-436 cells, wash with PBS, digest with 1 mL of trypsin for 1 min 45 s, then add 3 mL of 10% DMEM culture medium to stop digestion, gently blow down the cells and divide them into EP tubes; (2) Centrifuge at 3000 rpm, 4 ℃ for 5 min, discard the supernatant, resuspend the precipitate in 100 μL 0.01 M Tris-Mg, and disrupt the cells (ultrasound for 5 s, stop for 10 s, 5 min, power 20%); (3) Centrifuge at 11200 rpm, 4 ℃ for 15 min, discard the supernatant containing cell contents, resuspend the precipitate in 150 μL 0.01 M Tris-Mg buffer, and add sucrose solution with a final concentration of 0.25 μM; (4) Centrifuge at 2000 g, 4 ℃ for 10 min, further remove the organelle precipitate, and take the supernatant; (5) Centrifuge at 3000 g, 4 ℃ for 30 min, discard the supernatant containing cell contents, and resuspend the precipitate, which is the cell membrane (CM-MDA), in 100 μL PBS. Figure 2 As shown in B, the cell membrane is vesicle-like.

[0031] 2. (TDA) x Co y Synthesis and Application of Tb (TCT) 0.3 mmol 2,2'-thiodiacetic acid (TDA) and 0.2 mmol Co 2+Dissolve in 10 mL of deionized water, shake for 30 min, and add 0.2 mmol Tb 3+ , continue shaking for 30 min to obtain the complex (TDA) x Co y Tb (x, y = 1, 2 or 3).

[0032] (TDA) prepared according to the above preparation method x Co y Tb can be directly used to label biofilm vesicles or added during the co-incubation of biofilm vesicles and cells. Specifically: a: Enhanced targeting of biomembrane vesicles: 8-16 μL 0.1 mg / mL (TDA) x Co y After Tb was fully mixed with 10 μL of 0.30 mg / mL biomembrane vesicles (EXO-MDA or CM-MDA), the mixture was incubated at room temperature for 1-2 h, and then centrifuged at 4 °C, 3000 g for 20 min. The supernatant was removed, and the precipitate was resuspended in 100 μL of PBS to measure its particle size. Figure 3 As indicated, add 8-16 μL of 0.1 mg / mL (TDA) x Co y EXO-MDA (Tb Figure 3 A) and CM-MDA ( Figure 3 There was no significant change in particle size in B), so 0.1 mg / mL (TDA) was selected. x Co y Tb was used as the subsequent modification concentration.

[0033] b: Enhanced targeting during incubation: in (TDA) x Co y During the co-incubation of Tb-modified biofilm vesicles with cells, 8 μL of 0.1 mg / mL (TDA) was added x Co y Tb, further enhancing targeting.

[0034] 3. (TDA) x Co y Demonstration of Tb's ability to enhance homologous targeting Preparation of CM-MDA labeled with HAL and TCT: 10 μL of 0.30 mg / mL CM-MDA was mixed with 50 μL of 0.5 mM 5-aminolevulinic acid hexyl ester hydrochloride (HAL) for 1 min, and then 8.0 μL of 0.1 mg / mL TCT solution was added. The mixture was incubated for 2 h, centrifuged at 3000 g for 20 min, and the CM-MDA labeled with HAL and TCT was resuspended in 100 μL PBS.

[0035] Add 20 MDA-MB-436 cells to 100 μL DMEM medium and 100 μL labeled with 0.5 mM HAL and 0.1 mg / mL (TDA) x Co y Tb in CM-MDA containing 8 μL 0.1 mg / mL (TDA) x Co y Tb and without 8 μL 0.1mg / mL (TDA) x Co y Incubate at 37 °C for 1 h in the Tb system. Centrifuge at 2000 g, 25 °C for 5 min, discard the supernatant, and resuspend the precipitate in 500 μL DMEM medium. Add (TDA) in a 12-well plate. x Co y Tb group (+Tb) and no addition (TDA) x Co y In the Tb group (-Tb), 1 mL of MDA-MB-436 cells (approximately 10 6 After 24 h, the original culture medium was discarded, 500 μL of sample solution containing 0.5 mM HAL was added to 500 μL DMEM culture medium and mixed, and then added to the sample wells. After incubation for 3 h, the fluorescence intensity was detected using an inverted fluorescence microscope. Figure 4 As shown, the results showed that after adding CM-MDA labeled with HAL and TCT and co-incubating (TDA) x Co y After Tb, the red fluorescence intensity increased significantly, indicating that (TDA) x Co y Tb enhances the targeting ability of biomembrane vesicles. Example 2

[0036] Method development and optimization (1) Optimization of incubation time: 20 MDA-MB-436 cells were added to 100 μL DMEM medium and incubated with 100 μL labeled with 0.5 mM HAL and 0.1 mg / mL (TDA). x Coy CM-MDA of Tb and 8 μL 0.1 mg / mL (TDA) x Co y Tb were incubated at 37 °C for 10 min, 20 min, 30 min, 60 min, and 90 min. The pellet was centrifuged at 2000 g at 25 °C for 5 min, the supernatant was discarded, and the precipitate was resuspended in 500 μL DMEM medium and disrupted with a cell disruptor to release HAL. A blank group and a sample group were set up in a 12-well plate, and 1 mL of MDA-MB-436 cells (about 10 6 After 24 hours, the original culture medium was discarded, 500 μL of HAL-containing sample solution was added to 500 μL of DMEM culture medium and mixed, and then added to the sample well. After incubation for 4 hours, the fluorescence intensity was detected using a flow cytometer (BD FACSCelesta). Figure 5 As shown, when the incubation time with CM-MDA was 30 min, the fluorescence intensity value was the highest, so the CM-MDA incubation time was determined to be 30 min.

[0037] (2) Screening of HAL concentration: 20 MDA-MB-436 cells were added to 100 μL DMEM medium and incubated with 100 μL labeled HAL at different concentrations (0.05-1.0 mM) and 0.1 mg / mL (TDA) x Co y CM-MDA of Tb and 8 μL 0.1 mg / mL (TDA) x Co y Tb was incubated at 37 °C for 1 h. Centrifuged at 2000 g, 25 °C for 5 min, the supernatant was discarded, and the pellet was resuspended in 500 μL of DMEM medium. The fluorescence was detected using the subsequent method of optimizing the incubation time. Figure 6 As shown, when 0.5 mM HAL was selected as the final concentration used, the fluorescence intensity obtained by the flow cytometer reached the highest level. Therefore, 0.5 mM HAL was selected as the final modification concentration of the biomembrane vesicles in subsequent examples. Example 3

[0038] Homologous targeting enhanced biomembrane vesicle detection CTC specificity test and sensitivity test (1) Specificity test: 100 μL CM-MDA labeled with 40 μL PKH67 working solution was added to 8 μL 0.1 mg / mL (TDA) x Co y Tb and without 8 μL 0.1 mg / mL (TDA) x Co yTb system at 37 °C for 1 h. Centrifuge at 2000g, 25 °C for 5 min, discard the supernatant, and resuspend the precipitate in 500 μL DMEM medium to obtain CM-MDA-PKH67. Set up multiple cell groups in a 12-well plate, including MDA-MB-436, B16, HepG2, and L02 groups. Use the subsequent method of optimizing the incubation time in Example 2, and use an inverted fluorescence microscope to detect its fluorescence signal. Figure 7 As shown in the figure, only the MDA-MB-436 group in the system emits strong green fluorescence, and the other cell groups have no signal value, so the material has high specificity; and the addition of (TDA) x Co y The fluorescence intensity of the group with Tb was higher than that without TDA. x Co y The Tb group is stronger, which further indicates that the metal complex (TDA) x Co y Tb enhances the homologous targeting ability of biomembrane vesicles.

[0039] (2) Sensitivity test: Different numbers (1, 2, 3, 5, 10, 20) of MDA-MB-436 cells were added to 100 μL of DMEM culture medium and incubated with 100 μL of 0.5 mM HAL and 0.1 mg / mL (TDA) labeled x Co y Tb CM-MDA and 8 μL 0.1 mg / mL (TDA) x Co y Tb were incubated at 37 °C for 30 min. The cells were centrifuged at 2000 g at 25 °C for 5 min, the supernatant was discarded, and the precipitate was resuspended in 500 μL DMEM medium. The subsequent method for optimizing the incubation time in Example 2 was used to detect cells that produced PpIX fluorescence using a flow cytometer. Figure 8 As shown, the detection range of flow cytometry is 1 to 20 There is a good linear relationship within CTC / mL. Example 4

[0040] Detection of CTCs in the blood of normal and breast cancer mice by flow cytometry Extraction of peripheral blood mononuclear cells (PBMC): remove the mouse eyeball and collect about 1 mL of blood into a centrifuge tube with sodium heparin, add about 2 mL of lymphocyte separation solution into the test tube, gently blow and mix the anticoagulated blood, and then slowly drip it on the surface of the separation solution, centrifuge horizontally at 500×g for 30 min, carefully aspirate the mononuclear cell layer, centrifuge with 2 mL of DMEM culture medium (300×g, 10 min), wash twice to obtain PBMC, and set aside.

[0041] (2) Add the extracted PBMC to 100 μL DMEM medium and 100 μL labeled with 0.5 mM HAL and 0.1 mg / mL (TDA) x Co y CM-MDA of Tb and 8 μL 0.1 mg / mL (TDA) x Co y Tb was incubated at 37°C for 30 min. Centrifuged at 2000g, 25°C for 5 min, the supernatant was discarded, and the precipitate was resuspended in 500 μL DMEM medium. The subsequent method of optimizing the incubation time in Example 2 was used to measure the fluorescence signal using a flow cytometer. Fig. 9 As shown in A and B, there is a significant difference in the fluorescence signal between the normal mouse group and the cancer mouse group; Fig. 9 As shown in C, the AUC value of the ROC curve is 0.9689.

Claims

1. A method for detecting circulating tumor cells, It is characterized in that The following steps are involved: Step 1, taking tumor cells and preparing biomembrane vesicles; Step 2, taking the biomembrane vesicle solution, adding 5-aminolevulinic acid hexyl ester hydrochloride solution, mixing, and then adding the metal complex TDA-Co-Ln solution, incubating at room temperature and centrifuging to obtain targeted enhanced biomembrane vesicles; Step 3, taking the targeted enhanced biomembrane vesicle solution, adding the homologous tumor cell suspension / peripheral blood mononuclear cell suspension and the metal complex TDA-Co-Ln solution, incubating and centrifuging, ultrasonically disrupting the precipitate to release the HAL therein, and then incubating with the homologous tumor cells, detecting the fluorescence signal of the tumor cells that produce PpIX fluorescence by flow cytometry, and substituting it into the established standard curve to calculate the number of circulating tumor cells; The metal complex TDA-Co-Ln is composed of 2,2'-thiodiacetic acid, cobalt ion Co 2+ and lanthanide ions, wherein the lanthanide ions are Eu 3+ or Tb 3+ .

2. The method according to claim 1, It is characterized in that The biomembrane vesicles are cell membrane vesicles, extracellular vesicles or exosomes.

3. The method according to claim 1, It is characterized in that The specific process of step 2 is: take 10-20 μL of 0.03-0.30 mg / mL biomembrane vesicle solution, add 20-80 μL of 0.05-1.0 mM 5-aminolevulinic acid hexyl ester hydrochloride solution, mix well, then add 8-16 μL of 0.1 mg / mL metal complex TDA-Co-Ln solution, incubate at room temperature for 1-2 h, then centrifuge, and resuspend the precipitate with 100-200 μL PBS.

4. The method according to claim 3, It is characterized in that The concentration of the 5-aminolevulinic acid hexyl ester hydrochloride solution is 0.5 mM.

5. The method according to claim 1, It is characterized in that The specific process of step 3 is as follows: take 50-100 μL of the targeted enhanced biofilm vesicle solution, add 50-100 μL of homologous tumor cell suspension / peripheral blood mononuclear cell suspension and 8-16 μL of 0.1 mg / mL metal complex TDA-Co-Ln solution, incubate at 37 °C for 10-90 min, centrifuge, ultrasonically disrupt the precipitate to release the HAL, and then mix with 10 6 Tumor cells were incubated for 0.5-6 h.

6. The method according to claim 5, It is characterized in that The targeted enhanced biofilm vesicle solution, the homologous tumor cell suspension and the metal complex TDA-Co-Tb solution were incubated at 37° C. for 30 minutes.